Comments on:

News Summary: Merck settles cholesterol drug suits

Back to the article » |
SUIT SETTLEMENT: Drugmaker Merck agreed to pay $688 million to settle two investor lawsuits over a long delay in releasing results of a study meant to show its blockbuster cholesterol drugs reduced plaque buildup in arteries. But it found that Merck's Zetia and Vytorin were no better than a cheap generic pill. MERCK RESPONSE: Merck admits no wrongdoing and said it was in its best interest to...

To learn more about commenting on and our community guidelines, please see our comments FAQ.